TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members

R Delahunty; L Nguyen; S Craig; B Creighton; D Ariyaratne; DW Garsed; E Christie; S Fereday; L Andrews; A Lewis; S Limb; A Pandey; J Hendley; N Traficante; N Carvajal; AB Spurdle; B Thompson; MT Parsons; V Beshay; M Volcheck; T Semple; R Lupat; K Doig; J Yu; XQ Chen; A Marsh; C Love; S Bilic; M Beilin; CB Nichols; C Greer; YC Lee; S Gerty; L Gill; E Newton; J Howard; R Williams; C Norris; AN Stephens; E Tutty; C Smyth; S O'connell; T Jobling; CJR Stewart; A Tan; SB Fox; N Pachter; J Li; J Ellul; G Mir Arnau; MA Young; L Gordon; L Forrest; M Harris; K Livingstone; J Hill; G Chenevix-Trench; PA Cohen; PM Webb; M Friedlander; P James; D Bowtell; K Alsop

Journal article

TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members

R Delahunty, L Nguyen, S Craig, B Creighton, D Ariyaratne, DW Garsed, E Christie, S Fereday, L Andrews, A Lewis, S Limb, A Pandey, J Hendley, N Traficante, N Carvajal, AB Spurdle, B Thompson, MT Parsons, V Beshay, M Volcheck Show all

Journal of Clinical Oncology | Published : 2022

DOI: 10.1200/JCO.21.02108

Download PDF

Abstract

PURPOSETubo-ovarian cancer (TOC) is a sentinel cancer for BRCA1 and BRCA2 pathogenic variants (PVs). Identification of a PV in the first member of a family at increased genetic risk (the proband) provides opportunities for cancer prevention in other at-risk family members. Although Australian testing rates are now high, PVs in patients with TOC whose diagnosis predated revised testing guidelines might have been missed. We assessed the feasibility of detecting PVs in this population to enable genetic risk reduction in relatives.PATIENTS AND METHODSIn this pilot study, deceased probands were ascertained from research cohort studies, identification by a relative, and gynecologic oncology clinic..

View full abstract

University of Melbourne Researchers

Dale Garsed Author

Elizabeth Christie Author

Julie Fereday Author

Nadia Traficante Author

Related Projects (7)

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

IMPROVING OUTCOMES FOR WOMEN WITH EPITHELIAL OVARIAN CANCER

THE MOLECULAR BIOLOGY OF HUMAN OVARIAN CANCER

The Fellowship would support Professor Bowtell, one of the world’s leading ovarian cancer researchers. His work focuses on clinical problems..

TRACEBACK - IDENTIFICATION OF WOMEN CARRYING GERMLINE BRCA1/2 MUTATIONS THROUGH A RETROSPECTIVE ANALYSIS OF PATIENTS DIAGNOSED WITH HIGH GRADE SEROUS OVARIAN CANCER

Inheriting a mutated-BRCA is associated with significant risk of developing cancer. It is a crucial diagnosis to make with proven procedures..

MOLECULAR AND SPATIAL CHARACTERIZATION OF DRUG RESISTANCE IN HUMAN OVARIAN CANCER

Ovarian cancer is the most deadly gynecologic cancer in Western women. Although initially responsive to chemotherapy, drug resistance common..

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

Supported by funding from the Australian Government under the Public Health and Chronic Disease Grant Program, The National Health and Medical Research Council/Cancer Australia Postgraduate Scholarship (R.D.: APP1133906), The Donald and Joan Wilson Foundation, and St John of God Subiaco Hospital. Personnel received additional support from the National Health and Medical Research Council of Australia: APP1117044 (D.B.), APP1092856 (D.B. and M.F.), GNT1173346 (P.M.W.), APP177524 (A.B.S. and M.T.P.), APP1186505 (D.W.G.), and APP1161198 (E.C.). D.W.G. was supported by US Army Medical Research and Materiel Command grant W81XWH-16-2-0010. S.L. was supported by an Australian Government Research Training Program Scholarship and a Peter MacCallum Cancer Foundation Postgraduate Award. The Australian Ovarian Cancer Study was supported by the US Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania, The Cancer Foundation of Western Australia (Multi-State Applications 191, 211, and 182), and the National Health and Medical Research Council of Australia (NHMRC; ID199600, ID400413, and ID400281). The OPAL Study was funded by the National Health and Medical Research Council (NHMRC) of Australia (GNT1025142 and GNT1073898) and Brisbane Women's Club.